Post Covid-19 Mucormycosis (Black fungus): A Cases Report

Author:

Singh Dharmshktu Ishwar1,Rawat Sarita2,Dhaundhiyal Karuna3,Pathak Sachchidanand4,Keshari Vivek4,Kumar Deepak4,Singh Kamlesh4,Mishra Anurag5

Affiliation:

1. Assistant Professor, Department of Orthopedics, Dr. Susheela Tiwari Government Hospital and Medical College Haldwani Nanital Uttarakhand.

2. Amrapali Group of Institute, Haldwani Nainital Uttarakhand.

3. Junior Resident- SMS Medical College, Jaipur, Rajasthan.

4. Kashi Institute of Pharmacy, Mirzamurad, Varanasi.

5. Nims Institute of Pharmacy, NIMS University Jaipur Rajasthan.

Abstract

Objectives: COVID-19 (Coronavirus Disease 2019) infections have been related to a variety of fungal and bacterial co-infections. This case report includes the case of a COVID-19-infected patient who acquired rhino-orbital mucormycosis after undergoing COVID-19 treatment. We have discussed a COVID-19-infected patient who developed rhino-orbital mucormycosis during treatment in this case report8. Case Report: A 32-year-old female patient was admitted for treatment after testing positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR). She was later diagnosed with rhino-orbital mucormycosis. She received dexamethasone i.v BD and on Oxygen over the course of the admission; she developed symptoms of orbital cellulitis after few days. Soft tissue edoema was found in the left eye and paranasal sinuses on magnetic resonance imaging (MRI). A nasal biopsy revealed broad aseptate filamentous fungal hyphae, which led to the diagnosis of mucormycosis. Conclusions: The use of steroids and oxygen therapy often may result in the development or worsening of a fungal infection. Doctors should be concerned about the possibility of secondary invasive fungal infections in patients who already have COVID-19 infection.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3